Minnesota Congressman Among 60 Raising Objections to FDA Compounding Final Guidance

From NCPA Advocacy Center Update, June 3: In a letter to Scott Gottlieb, commissioner of the Food and Drug Administration, Reps. Chris Stewart (R-Utah), Buddy Carter (R-Ga.), Collin Peterson (D-Minn.) and more than 60 other members of Congress expressed their "strong disappointment" with the final Guidance for Industry (GFI) issued by the FDA on Dec. 29, 2016, titled the "Prescription Requirement under 503A of the Food, Drug and Cosmetic Act."

The letter points out that the final GFI takes the position that state-licensed pharmacies cannot compound medications pursuant to state pharmacy laws for administration to patients in office or clinical settings (commonly referenced to as "office-use compounding"). In the letter, the lawmakers state that office-use compounding is a common and often necessary medical practice that is authorized in some form by the vast majority of state pharmacy laws. NCPA staff and our pharmacy partners worked together to raise awareness of the letter and generate additional signatures.

We encourage you to thank Rep. Peterson for his work on behalf of pharmacy and pharmacists, whether you live in his district or not. You can send an email https://collinpeterson.house.gov/contact-me/email-me through his website.